SCHEMBL16699845

SCHEMBL16699845

Cc1nc(N)c(CCC2CCN(C(=O)OC(C)(C)C)CC2)c(O)n1

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MBOAT4 Q96T53 7/20 0.49
FAAH O00519 1/20 0.42
GPR119 Q8TDV5 6/20 0.41
DPP4 P27487 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
GLS O94925 1/20 0.41
BACE1 P56817 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20009391 0.90 MBOAT4 (0.50) MBOAT4FAAHGPR119DPP4KDM4E
SCHEMBL16699034 0.88 MBOAT4 (0.63) MBOAT4FAAHGPR119DPP4KDM4E
SCHEMBL16699688 0.85 MBOAT4 (0.53) MBOAT4
SCHEMBL18166117 0.84 MBOAT4 (0.59) MBOAT4FAAHGPR119DPP4KDM4E
SCHEMBL28406440 0.84 MBOAT4 (0.59) MBOAT4FAAHGPR119DPP4KDM4E
SCHEMBL28406437 0.84 MBOAT4 (0.59) MBOAT4FAAHGPR119DPP4KDM4E
SCHEMBL18154031 0.81 MBOAT4 (0.53) MBOAT4FAAHGPR119KDM4EPKM
SCHEMBL16718693 0.80 MBOAT4 (0.44) MBOAT4
SCHEMBL19991495 0.80 MBOAT4 (0.65) MBOAT4FAAHGPR119DPP4KDM4E
SCHEMBL18166101 0.74 MBOAT4 (0.61) MBOAT4KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3068775-B1 SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR LILLY CO ELI (US) 2017-09-06 EP disclosed
EP-3068775-B1 SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR LILLY CO ELI (US) 2017-09-06 EP disclosed
WO-2015073281-A1 SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR ELI LILLY AND COMPANY (US) 2015-05-21 WO disclosed
US-9035051-B1 Ghrelin O-acyl transferase inhibitor ELI LILLY AND COMPANY (US) 2015-05-19 US disclosed
US-9035051-B1 Ghrelin O-acyl transferase inhibitor ELI LILLY AND COMPANY (US) 2015-05-19 US disclosed
US-9035051-B1 Ghrelin O-acyl transferase inhibitor ELI LILLY AND COMPANY (US) 2015-05-19 US disclosed
US-20150133474-A1 GHRELIN O-ACYL TRANSFERASE INHIBITOR ELI LILLY AND COMPANY 2015-05-14 US disclosed
US-20150133474-A1 GHRELIN O-ACYL TRANSFERASE INHIBITOR ELI LILLY AND COMPANY 2015-05-14 US disclosed
US-20150133474-A1 GHRELIN O-ACYL TRANSFERASE INHIBITOR ELI LILLY AND COMPANY 2015-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133474-A1 GHRELIN O-ACYL TRANSFERASE INHIBITOR MBOAT4, DGAT1, MOGAT2 MBOAT4 1/4885FAAH 754/4885GPR119 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.